AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33880555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively, intravenously every 3 weeks ×4, followed by nivolumab 3 mg/kg every 2 weeks until progression, unacceptable toxicity, or 24 months)
Number of subjects: 119
Study 33880939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet analgesia
Number of subjects: 0
Study 33880939 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33881209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib (LY2606368) administered intravenously on days 1 and 15 of a 28-day cycle at dose levels of 80, 100, 125, and 150 mg/m²
Number of subjects: 30
Study 33881400 — intervention group
Group type: EXPERIMENTAL
Intervention: V-LAP technology (intracardiac microsensors)
Number of subjects: 14
Study 33881463 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 0
Study 33881463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33881718 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishe Pill (3-4 g/kg for 4 weeks)
Number of subjects: 2023
Study 33881949 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with community stakeholders
Number of subjects: 0
Study 33881949 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33882028 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP 360 nutraceutical energy formula for 8 weeks
Number of subjects: 11
Study 33882070 — intervention group
Group type: EXPERIMENTAL
Intervention: eNose-TB screening tool
Number of subjects: 1778
Study 33882070 — intervention group
Group type: COMPARATOR
Intervention: Clinical symptoms and chest radiology (standard screening)
Number of subjects: 1778
Study 33882070 — intervention group
Group type: EXPERIMENTAL
Intervention: eNose-TB screening algorithm
Number of subjects: 1778
Study 33882092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (BCPP interventions to improve linkage to care, retention, viral load coverage, and service delivery)
Number of subjects: 3657
Study 33882092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Tracking and tracing efforts)
Number of subjects: 3657
Study 33882092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Retention in care)
Number of subjects: 3657
Study 33882092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Viral load results)
Number of subjects: 3657
Study 33882143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 19
Study 33882147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) use
Number of subjects: 700
Study 33882147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) use (adjusted for prior MPA discontinuation)
Number of subjects: 700
Study 33882374 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in cancer patients
Number of subjects: 39
Study 33882374 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 infection in non-cancer patients
Number of subjects: 39
Study 33882698 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat challenge (HC) with 35°C exposure after acclimation to 27°C baseline (BL)
Number of subjects: 20
Study 33882792 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgHIFU (Profound Sonalleve)
Number of subjects: 11
Study 33882846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1α/IL-1β cytokine trap) administered weekly during a 6-week base treatment period plus an optional 18-week extension period.
Number of subjects: 25
Study 33882862 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) performed by a nurse and physician, adapted to primary care context, during a two-year follow-up period.
Number of subjects: 1308
Study 33882862 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 1308
Study 33883015 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite transcranial direct current stimulation combined with cognitive training (24 sessions, 30 minutes each, 3 times a week, with stimulation of different brain areas every 10 minutes).
Number of subjects: 2
Study 33883033 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinkCancer! intervention (educational behaviour change workshop for GPs)
Number of subjects: 30
Study 33883033 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 33883035 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM decision tool (CV PREVENTION CHOICE)
Number of subjects: 0
Study 33883035 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 0
Study 33883035 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM
Number of subjects: 0
Study 33883176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-177-PSMA-617
Number of subjects: 10
Study 33883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabatolimab plus spartalizumab
Number of subjects: 0
Study 33883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Number of subjects: 0
Study 33883177 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Number of subjects: 0
Study 33883194 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for coronary artery disease (CAD)
Number of subjects: 1371
Study 33883194 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 1371
Study 33883258 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-15 CIV-5, 3 µg (n=4)
Number of subjects: 11
Study 33883258 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-15 CIV-5, 4 µg (n=3)
Number of subjects: 11
Study 33883258 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-15 CIV-5, 5 µg/kg/day (n=4)
Number of subjects: 11
Study 33883548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free RNA (cfRNA) analysis in cancer patients
Number of subjects: 165
Study 33883548 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of dark channel biomarker (DCB) genes in cancer patients
Number of subjects: 165
Study 33883548 — intervention group
Group type: EXPERIMENTAL
Intervention: cfRNA as a cancer detection method
Number of subjects: 165
Study 33884298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 250
Study 33884298 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (control group)
Number of subjects: 250
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioural therapy (CBT)-based psychotherapy
Number of subjects: 21414
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 21414
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalisation-based therapy (MBT)
Number of subjects: 21414
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based emotion-regulation psychotherapy
Number of subjects: 21414
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Various forms of DBT (group-based skills training, individual skills training, experimental DBT)
Number of subjects: 21414
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of information and support (START and SUPRE-MISS models)
Number of subjects: 21414
Study 33884617 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy, case management, GP management, remote contact interventions, other multimodal interventions, brief emergency department-based interventions
Number of subjects: 21414
Study 33884961 — intervention group
Group type: EXPERIMENTAL
Intervention: PARPi treatment
Number of subjects: 13
Study 33884961 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro tumor treatment with a PARPi
Number of subjects: 13
Study 33885047 — intervention group
Group type: EXPERIMENTAL
Intervention: General and epidural anesthesia during elective knee replacement surgery
Number of subjects: 18
Study 33885048 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 72
Study 33885369 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI) using animated health videos and InfoSpots; exposure to 3 different health animations once on a tablet device.
Number of subjects: 600
Study 33885369 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI)
Number of subjects: 600
Study 33885369 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 600
Study 33885368 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Walk intervention delivered through smartphone app and text messages
Number of subjects: 20
Study 33885368 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Walk intervention
Number of subjects: 20
Study 33886075 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-of-Flight surface imaging technique for tidal volume measurement
Number of subjects: 0
Study 33886075 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-of-Flight surface imaging technique for respiratory rate measurement
Number of subjects: 0
Study 33886085 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 127
Study 33886085 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 127
Study 33886085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 33886789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectasis group
Number of subjects: 74
Study 33887060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough augmentation techniques (manual assisted cough, mechanical insufflation, manual and mechanical breathstacking, mechanical insufflation-exsufflation, glossopharyngeal breathing, combination techniques)
Number of subjects: 287
Study 33887060 — intervention group
Group type: COMPARATOR
Intervention: Alternative cough augmentation techniques
Number of subjects: 287
Study 33887060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough augmentation techniques
Number of subjects: 287
Study 33887074 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 9556
Study 33887074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Use
Number of subjects: 9556
Study 33887074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Consumption
Number of subjects: 9556
Study 33887074 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Gain
Number of subjects: 9556
Study 33887074 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Behaviors
Number of subjects: 9556
Study 33887074 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 9556
Study 33887119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography
Number of subjects: 41
Study 33888067 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (1-15 mg/day)
Number of subjects: 510
Study 33888232 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Transcatheter Heart Valves
Number of subjects: 0
Study 33888241 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33888530 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported assessment of shoulder function (Oxford Shoulder Score (OSS)) at 6 months post-surgery
Number of subjects: 970
Study 33888530 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder stiffness occurrence at 6 months post-surgery
Number of subjects: 970
Study 33888530 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder range of motion and strength (Constant Score) at 6 and 12 months post-surgery
Number of subjects: 970
Study 33888530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon repair integrity status assessed by ultrasound at 12 months post-surgery
Number of subjects: 970
Study 33888530 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported questionnaires at 6, 12, and 24 months for functional scores, anxiety and depression scores, working status, sports activities, and quality of life (European Quality of Life 5 Dimensions 5 Level questionnaire)
Number of subjects: 970
Study 33888530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) documented according to a consensus core event set (CES)
Number of subjects: 970
Study 33888591 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cognitive dysfunction
Number of subjects: 142
Study 33888591 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Component Score (PCS)
Number of subjects: 142
Study 33888591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Component Score (MCS)
Number of subjects: 142
Study 33888591 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cognitive changes
Number of subjects: 142
Study 33888899 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-1BB-costimulated CD22 CAR T cells
Number of subjects: 0
Study 33888899 — intervention group
Group type: COMPARATOR
Intervention: CD19-directed CAR T cells
Number of subjects: 0
Study 33888901 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) administered orally at 120 mg once daily in patients with ccRCC (n=55)
Number of subjects: 98
Study 33888901 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) administered orally at various doses in dose-escalation cohort (n=43)
Number of subjects: 98
Study 33888901 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) administered orally at various doses
Number of subjects: 98
Study 33888901 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482)
Number of subjects: 98
Study 33888974 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior chamber intraocular lenses implantation during cataract surgery
Number of subjects: 34
Study 33889025 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1965
Study 33889025 — intervention group
Group type: COMPARATOR
Intervention: Clinician diagnosis
Number of subjects: 1965
Study 33889959 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHR SNPs (rs6165, rs6166, rs1394205)
Number of subjects: 368
Study 33889959 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHR SNPs (rs1394205)
Number of subjects: 368
Study 33889959 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHR variant rs6166
Number of subjects: 368
Study 33889959 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHR variant rs6165
Number of subjects: 368
Study 33890058 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (14 days)
Number of subjects: 25
Study 33890058 — intervention group
Group type: COMPARATOR
Intervention: Metreleptin withdrawal (14 days)
Number of subjects: 25
Study 33890580 — intervention group
Group type: EXPERIMENTAL
Intervention: GIMEMA-ALLIANCE digital health platform
Number of subjects: 116
Study 33890856 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartBeat algorithm using MediBeat app and Contec CMS50EW pulse oximeter
Number of subjects: 62
Study 33890856 — intervention group
Group type: COMPARATOR
Intervention: Manual blood pressure measurement
Number of subjects: 62
Study 33890857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB intervention (smartphone-delivered, home-based PA intervention)
Number of subjects: 50
Study 33890857 — intervention group
Group type: COMPARATOR
Intervention: Attention-control education condition
Number of subjects: 50
Study 33890857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB intervention
Number of subjects: 50
Study 33891139 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green retention rate at 15 min (ICG-R15)
Number of subjects: 50
Study 33891139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic Venous Portal Gradient (HVPG)
Number of subjects: 50
Study 33891250 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative perfusion index
Number of subjects: 0
Study 33891250 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in preoperative baseline perfusion index (ΔPI-pre)
Number of subjects: 0
Study 33891250 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in postoperative perfusion index (ΔPI-po)
Number of subjects: 0
Study 33891293 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 200 mg IV once, followed by 100 mg IV once daily for ≥ 5 to ≥ 10 days, with a switch to oral voriconazole/fluconazole permitted in all but one study.
Number of subjects: 139
Study 33891293 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin treatment
Number of subjects: 139
Study 33891312 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental dural puncture
Number of subjects: 270
Study 33891312 — intervention group
Group type: COMPARATOR
Intervention: Control (uneventful epidural insertion)
Number of subjects: 270
Study 33891621 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care EoE treatment for 2 months
Number of subjects: 25
Study 33892094 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led group yoga sessions (8 sessions)
Number of subjects: 15
Study 33892111 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (MPH-MLR)
Number of subjects: 90
Study 33892122 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant Evo thoracic stent graft system
Number of subjects: 83
Study 33892407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) + Metronomic cyclophosphamide (25 mg/m2)
Number of subjects: 13
Study 33892407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Metronomic cyclophosphamide
Number of subjects: 13
Study 33892489 — intervention group
Group type: EXPERIMENTAL
Intervention: GARFIELD-AF risk tool
Number of subjects: 52080
Study 33892660 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriSTEP® single question on food insecurity
Number of subjects: 1174
Study 33892660 — intervention group
Group type: COMPARATOR
Intervention: Hunger Vital Sign™
Number of subjects: 1174
Study 33892693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 214
Study 33892693 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptives
Number of subjects: 214
Study 33892740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladnaan, a culturally tailored parenting program
Number of subjects: 0
Study 33892740 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 33893160 — intervention group
Group type: EXPERIMENTAL
Intervention: APL9 score based on genomic and transcriptomic analysis
Number of subjects: 348
Study 33893160 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular markers identified in the study
Number of subjects: 348
Study 33893174 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided thoracic epidural catheter placement
Number of subjects: 38
Study 33893210 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive subjects receiving antiviral treatment (32%)
Number of subjects: 510
Study 33893210 — intervention group
Group type: COMPARATOR
Intervention: HIV negative subjects receiving antiviral treatment (6%)
Number of subjects: 510
Study 33893289 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA sequencing
Number of subjects: 800
Study 33893289 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant treatment
Number of subjects: 800
Study 33893692 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1,500 mg every 4 weeks × 13) and Tremelimumab (75 mg Q4 weeks × 7, then Q12 weeks × 2)
Number of subjects: 50
Study 33893973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of N-acetylmannosamine (ManNAc)
Number of subjects: 34
Study 33893973 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylmannosamine (ManNAc)
Number of subjects: 34
Study 33894353 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed symptomatic dengue infection
Number of subjects: 3300
Study 33894353 — intervention group
Group type: EXPERIMENTAL
Intervention: Inapparent primary dengue infection
Number of subjects: 3300
Study 33894474 — intervention group
Group type: EXPERIMENTAL
Intervention: High NETs group (60 patients)
Number of subjects: 104
Study 33894474 — intervention group
Group type: COMPARATOR
Intervention: Low NETs group (44 patients)
Number of subjects: 104
Study 33894633 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Tumor Cell (CTC) count determined on the Epic Sciences platform
Number of subjects: 278
Study 33894633 — intervention group
Group type: COMPARATOR
Intervention: CTC enumeration using CellSearch® Circulating Tumor Cell Kit
Number of subjects: 278
Study 33894747 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted lateral position with personalized PEEP
Number of subjects: 5
Study 33894747 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 5
Study 33894753 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of ASESp (ASESp-CH)
Number of subjects: 86
Study 33895322 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAd-COV2 vaccine
Number of subjects: 0
Study 33895322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-fusion stabilized Spike antigen
Number of subjects: 0
Study 33895695 — intervention group
Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016
Number of subjects: 20446
Study 33895695 — intervention group
Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016 in HER2+ subcohort
Number of subjects: 20446
Study 33895695 — intervention group
Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016 in TNBC
Number of subjects: 20446
Study 33895695 — intervention group
Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016 in HR+/HER2-
Number of subjects: 20446
Study 33895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to newly released anti-HER2 therapies (e.g. pertuzumab) from 2016 onwards
Number of subjects: 20446
Study 33895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of everolimus or eribulin in HR+/HER2- and TNBC cohorts
Number of subjects: 20446
Study 33895711 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted partner services (APS) using community-embedded peer educators (PEs) to identify and link partners to care.
Number of subjects: 1000
Study 33895716 — intervention group
Group type: EXPERIMENTAL
Intervention: Existential distress assessment through self-report questionnaires and structured diagnostic interviews at baseline and 6-month follow-up.
Number of subjects: 1000